Increased Cyclosporine Concentrations in the Absence of Cyclosporine Administration

Andreas Peter, * Maria Shipkova, Eberhard Wieland, Erwin Schleicher, and Ingo Müller

1 Department of Internal Medicine, Division of Endocrinology, Metabolism, Pathobiochemistry and Clinical Chemistry, University of Tübingen, Tübingen, Germany; 2 Central Institute for Clinical Chemistry and Laboratory Medicine, Klinikum Stuttgart, Stuttgart, Germany; 3 Department of General Paediatrics, Haematology, Oncology, University Children's Hospital, Tübingen, Germany.

* Address correspondence to this author at: Department of Internal Medicine, Division of Endocrinology, Metabolism, Pathobiochemistry and Clinical Chemistry, University of Tübingen, Offfried-Müller-Str. 10, 72076 Tübingen, Germany. Fax +49-7071-294582; e-mail andreas.peter@med.uni-tuebingen.de.

CASE

A 9-year-old girl was admitted to our hospital with juvenile metachromatic leukodystrophy (arylsulfatase A deficiency). Symptoms of this lysosomal storage disease, such as decreased school performance and compromised motor skills, had started 1 year earlier. She underwent bone marrow transplantation from a matched unrelated donor after receiving conditioning with fludarabine, treosulfan, and thiotepa, together with thymoglobulin, a rabbit antithymocyte globulin. Conditioning was well tolerated, and the posttransplantation period was uneventful except for 1 febrile episode. Graft-vs-host disease (GvHD) prophylaxis consisted of 3 methotrexate doses in combination with a starting daily cyclosporin A (CsA) dosage of 3 mg · kg⁻¹ · day⁻¹. Trough CsA concentrations were monitored with the antibody-conjugated magnetic immunoassay (ACMIA) for CsA (RxL Dimension; Siemens). CsA concentrations entered the therapeutic interval after 3 days, and the dosage was adjusted to achieve trough concentrations of 120–150 µg/L (Fig. 1). The patient received CsA for 16 weeks. During this period, the CsA concentration was measured 31 times, with results from 98 µg/L to 219 µg/L (mean, 156 µg/L). Four weeks after transplantation, the patient developed a mild GvHD of the skin, which disappeared immediately after commencement of prednisolone treatment. Because B lymphocytes were absent or low early after transplantation, the patient received immunoglobulins for 5 months (Fig. 1). Endogenous immunoglobulin production started only in the later phase of immune reconstitution. Six weeks after discontinuation of CsA therapy, a concentration of 147 µg/L was still detected in whole blood. Although the patient was not supposed to have received CsA and the parents had denied the administration of CsA or drugs other than those prescribed, CsA concentrations between 116 µg/L and 174 µg/L were obtained over the next 4 months.

Questions to Consider

- Has the CsA therapy really been discontinued?
- Can delayed drug elimination explain the continued increased CsA concentrations?
- What tests could be done to identify any potential analytical interference?
**Clinical Case Study**

![Graph showing time courses of whole-blood CsA concentration, administered daily CsA dose, and B-lymphocyte count over months.]

*Fig. 1.* Time courses of the whole-blood CsA concentration measured with the ACMIA CsA assay, the administered daily CsA dose, and the B-lymphocyte count.

---

**Final Publication and Comments**

The final published version with discussion and comments from the experts will appear in the May 2011 issue of *Clinical Chemistry*. To view the case and comments online, go to [http://www.clinchem.org/content/vol57/issue5](http://www.clinchem.org/content/vol57/issue5) and follow the link to the Clinical Case Study and Commentaries.

**Educational Centers**

If you are associated with an educational center and would like to receive the cases and questions 1 month in advance of publication, please email clinchem@aacc.org.

AACC is pleased to allow free reproduction and distribution of this Clinical Case Study for personal or classroom discussion use. When photocopying, please make sure the DOI and copyright notice appear on each copy.

All previous Clinical Case Studies can be accessed and downloaded online at [http://www.aacc.org/resourcecenters/casestudies/](http://www.aacc.org/resourcecenters/casestudies/).

---

AACC is a leading professional society dedicated to improving healthcare through laboratory medicine. Its nearly 10,000 members are clinical laboratory professionals, physicians, research scientists, and others involved in developing tests and directing laboratory operations. AACC brings this community together with programs that advance knowledge, expertise, and innovation. AACC is best known for the respected scientific journal, *Clinical Chemistry*, the award-winning patient-centered web site *Lab Tests Online*, and the world’s largest conference on laboratory medicine and technology. Through these and other programs, AACC advances laboratory medicine and the quality of patient care.